MedTrace Logo

Traditional vs. Posterior Nasal Radiofrequency Ablation for Chronic Rhinitis

NCT07323888 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-13

No results posted yet for this study

Summary

This study is a prospective, single-center, single-blinded randomized controlled trial designed to compare the clinical effectiveness of traditional radiofrequency ablation of the anterior inferior turbinate alone versus expanded radiofrequency ablation including the middle and posterior portions of the inferior turbinate (posterior nasal region). Patients with chronic rhinitis who remain symptomatic despite at least six months of medical therapy will be randomized in a 2:1 ratio to undergo extended posterior nasal ablation versus traditional anterior treatment. Symptom improvement will be evaluated using rTNSS and other validated questionnaires.

Conditions

  • Nasal Obstruction
  • Chronic Rhinitis
  • Nonallergic Rhinitis
  • Rhinorrhea
  • Inferior Turbinate Hypertrophy

Interventions

PROCEDURE

Traditional Radiofrequency Ablation of Inferior Turbinates With Posterior Nasal Radiofrequency Ablation

Intervention: Radiofrequency Ablation (Olympus Celon Elite ESG-400) * Local anesthesia with 2% lidocaine * RF ablation at 15W * Multiple punctures along anterior, middle, and posterior inferior turbinate (15-20 per side) * Includes posterior nasal region (superior, medial, inferior aspects) * No nasal packing required Post-operative care (3 days): 1. Tranexamic acid 250mg 1cap BID x3 days 2. Amoxicillin 500mg 1 cap BID x3 days 3. Acetaminophen 500mg 1tab BID x3 days 4. Levocetirizine 5mg 1tab QD x3 days + PRN x4 days

PROCEDURE

Traditional Radiofrequency Ablation of Inferior Turbinates

Intervention: Radiofrequency Ablation (anterior inferior turbinate only) * Same anesthesia and device * RF applied only to anterior inferior turbinate (≈2 punctures per side) * No treatment to middle/posterior inferior turbinate Post-operative care: Same as experimental arm

Sponsors & Collaborators

  • Chien Yu Huang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2027-04-05
Completion
2027-05-01

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07323888 on ClinicalTrials.gov